← All trials
NCT06045299
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 27, 2023
- Primary completion
- Jul 31, 2024
- Completion date
- Dec 31, 2024
- First posted
- Sep 21, 2023
- Last posted
- Oct 26, 2023
- Enrollment
- 300
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Ji Xing Pharmaceuticals (Shanghai) Co., Ltd.Lead sponsor
- Ji Xing Pharmaceuticals (Shanghai) Co., Ltd.Study director
- Presbyopia Therapies, LLCCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.